MIAMI CANCER INSTITUTE - NEW ADVANCES IN THE MANAGEMENT OF PANCREATIC CANCER
Tracking # 20-899665
$9.95
Course overview
Pancreatic cancer is a malignancy with poor prognosis and high mortality. The risk factors can be categorized as those related to individual characteristics, lifestyle and environment, and disease status. During this conference, a panel of experts that includes Dr. Domenech Asbun, Dr. Horacio Asbun, Dr. Michael Chuong, Dr. Ripal Gandhi, Dr. Ramon Jimenez, Dr. Govindarajan Narayanan and Dr. Fernando de Zarraga, will examine recently published trial data and review their implications for unresectable locally advanced pancreatic cancer care.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Medicine
Anesthesiologist Assistant
Area of Critical Need Medical Doctor
Medical Doctor
Medical Doctor Faculty Certificate
Medical Doctor Limited License
Medical Doctor Limited to Cleveland Clinic
Medical Doctor Limited to Mayo Clinic
Medical Doctor Public Health Certificate
Medical Doctor Public Psychiatry
Medical Doctor Visiting Faculty Certificate
Florida Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
Florida Board of Osteopathic Medicine
Osteopathic Physician
Florida Physician Assistants
Physician Assistant
Disclosure statements
Domenech Asbun, M.D.
Hepatobiliary and Pancreatic Surgery
Miami Cancer Institute
Miami, Florida
Ramon E. Jimenez, M.D.
Surgical Oncology
Sarcoma and Connective Tissue Surgical Oncology
Miami Cancer Institute
Domenech Asbun, M.D., and Ramon E. Jimenez, M.D., faculty for this educational activity, have no relevant financial relationships with ineligible companies* to disclose and have indicated that the presentations or discussions will not include off-label or unapproved product usage.
Horacio J. Asbun, M.D.
Chief of Hepatobiliary & Pancreatic Surgery
Baptist Health Medical Group, Miami Cancer Institute, Baptist Health South Florida
Horacio J. Asbun, M.D., faculty for this educational event, is a consultant with Johnson & Johnson, Boston Scientific and Olympus, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.
Michael Chuong, M.D., FACRO
Medical & Clinical Research Director
GI Service Lead, Dept. of Radiation Oncology, Miami Cancer Institute
Associate Professor, Vice Chair of Research and Education
Florida International University
Michael Chuong, M.D., FACRO, faculty for this educational activity, is a researcher for ViewRay, Novocure and AstraZeneca; a consultant and adviser for ViewRay; an adviser for Advanced Accelerator Applications; and a member of the speakers’ bureau for ViewRay, Elekta and Sirtex. Dr. Chuong has indicated that the presentation or discussion will not include off-label or unapproved product usage.
Ripal Gandhi, M.D.
Miami Cancer Institute and Miami Cardiac & Vascular Institute
Associate Clinical Professor, Florida International University Herbert Wertheim College of Medicine
Associate Clinical Professor, University of South Florida School of Medicine
Ripal Gandhi, M.D., conference director and faculty for this educational activity, is a consultant for Sirtex, Medtronic, BD, Cordis and TriSalus Life Sciences, and has indicated that the presentation or discussion will include off-label or unapproved product usage.
Govindarajan Narayanan, M.D.
Chief of Interventional Oncology
Baptist Health South Florida
Professor of Radiology
Florida International University Herbert Wertheim College of Medicine
Govindarajan Narayanan, M.D., faculty for this educational activity, is a consultant with Angiodynamics, Varian, Boston Scientific, Stryker and Guerbet, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.
All relevant financial relationships listed for these individuals have been mitigated.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*.
*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.